ADRB1 as a Potential Target for Gene Therapy of Pregnancy Induced Hypertension and Gestational Diabetes Mellitus

Abstract

Pregnancy-induced hypertension (PIH) and gestational diabetes mellitus (GDM) do not cause any problems with recognition; however, their pathophysiologies are still not explained. Yet many authors suggest that adrenergic β–1 receptor (ADRB1) plays a crucial role. The aim of this study was to evaluate the transcription activity of ADRB1 by using real-time polymerase chain reaction (PCR) in placenta from normal pregnancies and from PIH and GDM. Obtained findings demonstrated a significant increase in ADRB1 mRNA expression in the examined groups in comparison to the control (p = 0.03). Our data indicate a potential perspective of ADRB1 suppression gene therapy in the treatment of PIH and GDM.

• adrenergic β–1 receptor
• placenta
• pregnancy-induced hypertension
• pregnancy diabetes
• gene therapy

ACKNOWLEDGMENT

The authors are grateful to the Government Department of Science in Warsaw for providing the opportunity to perform these studies.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.